Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia

Lipids in Health and Disease

Volumn 8, Issue , 2009, Pages

  Kumar, Shoba Sujana ^a,b   Lahey, Karen A ^c   Day, Andrew ^d   Lahaye, Stephen A ^e  

^a UNIVERSITY OF TORONTO   (Canada)

^b WOMEN S COLLEGE HOSPITAL   (Canada)

^c HOTEL DIEU HOSPITAL   (Canada)

^d KINGSTON GENERAL HOSPITAL   (Canada)

^e QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; AZETIDINE DERIVATIVE; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PYRROLE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BODY EQUILIBRIUM; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG EFFICACY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; MALE; MONOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; ADOLESCENT; BLOOD; COMPARATIVE STUDY; DEMOGRAPHY; DRUG COMBINATION; MIDDLE AGED; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, LDL; DEMOGRAPHY; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; HEPTANOIC ACIDS; HUMANS; MALE; MIDDLE AGED; PROCETOFEN; PYRROLES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 74549139066     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-8-56     Document Type: Article

References (23)

1. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. R Collins J Armitage S Parish, et al. Lancet 2002 360 7 22 10.1016/S0140-6736(02) 09327-3 12114036 (Pubitemid 34756487)
2. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. J Genest R McPherson J Frolich T Anderson N Campbell A Carpentier P Couture R Dufour G Fodor GA Francis S Grover M Gupta RA Hegele DC Lau L Leiter GF Lewis E Lonn GB Mancini D Ng GJ Pearson A Sniderman JA Stone E Ur, Can J Cardiol 2009 25 10 567 579 19812802
3. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. RC Pasternak SC Smith CN Bairey-Merz SM Grundy JI Cleeman C Lenfant American College of Cardiology, American Heart Association, National Heart, Lung, Blood Institute, Circulation 2002 106 1024 8 10.1161/01.CIR.0000032466.44170.44 12186811
4. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study. E Bruckert G Hayem S Dejager C Yau B Bégaud, Cardiovasc Drugs Ther 2005 19 403 14 10.1007/s10557-005-5686-z 16453090
5. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. RH Knopp H Gitter T Truitt H Bays CV Manion LJ Lipka AP LeBeaut R Suresh B Yang EP Veltri Ezetimibe Study Group, Eur Heart J 2003 24 729 741 10.1016/S0195-668X(02)00807-2 12713767
6. Ezetimibe: A review of its metabolism, pharmacokinetics, and drug interactions. T Kosoglou P Statkevich AO Johnson-Levonas JF Paolini AJ Bergman KB Alton, Clinical pharmacokinetics 2005 44 467 494 10.2165/00003088-200544050- 00002 15871634
7. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. HE Bays PB Moore MA Drehobl S Rosenblatt PD Toth CA Dujovne RH Knopp LJ Lipka AP Lebeaut B Yang LE Mellars C Cuffie-Jackson EP Veltri Ezetimibe Study Group, Clin Ther 2001 23 1209 30 10.1016/S0149-2918(01)80102-8 11558859
8. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia. CM Ballantyne J Houri A Notarbartolo, et al. Circulation 2003 107 2409 2415 10.1161/01.CIR.0000068312.21969.C8 12719279
9. Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe. T Kosoglou P Statkevich JC Fruchart, et al. Curr Med Res Opin 2004 20 1197 207 10.1185/030079903125004277 15324522
10. Efficacy and tolerability of a "suprabioavailable" formulation of fenofibrate in patients with dyslipidemia: A pooled analysis of two open-label trials. BR Ramjattan DJG Callaghan U Theiss, Clin Ther 2002 24 1105 1116 10.1016/S0149-2918(02)80022-4 12182255
11. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidemia. M Farnier MW Freeman G Macdonnell I Perevozskaya MJ Davies YB Mitchel, et al. Eur Heart J 2005 26 897 905 10.1093/eurheartj/ehi231 15781429
12. Safety and efficacy of long-term coadministration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. JM McKenney M Farnier KW Lo HE Bays I Perevozkaya G Carlson, et al. J Am Coll Cardio 2006 47 1584 1587 10.1016/j.jacc.2005.11.072
13. An assessment of statin safety by hepatologists. DE Cohen FA Anania N Chalasani, Am J Cardiol 2006 97 77C 81C 10.1016/j.amjcard.2005.12.014 16581333
14. An Assessment of statin safety by muscle experts. PD Thompson PM Clarkson RS Rosenson, Am J Cardiol 2006 97 69C 76C 10.1016/j.amjcard.2005.12.013 16581332
15. Simvastatin with or without ezetimibe in familial hypercholesterolemia. JJ Kastelein F Akdim ES Stroes AH Zwinderman ML Bots AF Stalenhoef, et al. N Engl J Med 2008 358 1431 43 10.1056/NEJMoa0800742 18376000
16. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. A Keech RJ Simes P Barter J Best R Scott MR Taskinen, et al. Lancet 2005 366 1849 61 10.1016/S0140-6736(05)67667-2 16310551
17. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, JAMA 2002 288 2998 3007 Fleiss JL. The Design and Analysis of Clinical Experiments. New York: Wiley, 1986 10.1001/jama.288.23.2998 12479764
18. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. C Baigent A Keech PM Kearney L Blackwell G Buck Pollicino, et al. Lancet 2005 366 1267 78 10.1016/S0140-6736(05)67394-1 16214597
19. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. The Heart Protection Study Collaborative Group, Lancet 2002 360 7 22 10.1016/S0140-6736(02)09327-3 12114036
20. JL Fleiss, The Design and Analysis of Clinical Experiments New York: Wiley 1986
21. The two-period crossover clinical trial. M Hills P Armitage, Br J Clin Pharm 1979 8 7 20
22. The crossover experiment for clinical trials. BW Brown, Biometrics 1980 36 69 79 10.2307/2530496 7370374
23. SAS Institute Inc, SAS/STAT User's Guide, Version 8 Cary, NC: SAS Institute Inc 1999